SWOG clinical trial number
CTSU/NRG-GI004

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Open
Phase
Abbreviated Title
COMMIT
Participants
CTSU, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Gastrointestinal Cancer
Symptom Control and Quality of Life

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2021

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)

M Overman;G Yothers;S Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;P Lucas;CD Blanke;N Wolmark;H Hochster;T George;SMS Rocha Lima J Clin Oncol 39, 2021 (suppl 3; abstr TPS158); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), TIPS, poster

2020

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG-GI004/SWOG-S1610)

CMS Rocha Lima;G Yothers;SA Jacobs;H Sanoff;DJ Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;PC Lucas;CJ Allegra;CD Blanke;N Wolmark;HS Hochster;TJ George;MJ Overman J Clin Oncol 38, 2020 (suppl 4; abstr TPS260); ASCO GI Cancers Symposium (January 23-25, 2020, San Francisco, CA)

2018

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/ bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer

J Lee;G Yothers;SA Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;PC Lucas;C Allegra;C Blanke;N Wolmark;H Hochster;TJ George;M Overman J Clin Oncol 36, 2018 (suppl; abstr TPS3615); ASCO Annual Meeting (June 1-5, 2018, Chicago, IL), poster session

Other Clinical Trials

SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
33%
Open
Phase
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Research Committee(s)
Symptom Control and Quality of Life
Activated
01/17/2023
Accrual
92%
Open
Phase
SWOG Clinical Trial Number
EAQ202

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase